GSK 576389A

Drug Profile

GSK 576389A

Alternative Names: FluAS25 adjuvanted influenza vaccine - GlaxoSmithKline; FluAS25 adjuvanted inluenza vaccine - GlaxoSmithKline; GSK576389A; Seasonal influenza virus vaccine - GlaxoSmithKline

Latest Information Update: 14 Feb 2014

Price : $50

At a glance

  • Originator GlaxoSmithKline
  • Class Influenza virus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Influenza virus infections

Most Recent Events

  • 01 Jan 2011 Discontinued prior to 2011 - Phase-III for Influenza virus infections (prevention in the elderly) in USA, Germany and Norway (IM)
  • 01 Jan 2011 Discontinued prior to 2011- Phase-II for Influenza virus infections (prevention in the elderly) in Denmark, Belgium, Netherlands, Estonia, United Kingdom and Sweden (IM)
  • 01 Oct 2007 Phase-II clinical trials in Influenza virus infections (prevention in the elderly) in Belgium, United Kingdom, Germany, Netherlands and Sweden (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top